Vahid Mirshafiee
Overview
Explore the profile of Vahid Mirshafiee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Du Q, Ge D, Mirshafiee V, Chen C, Li M, Xue C, et al.
Nanoscale
. 2019 Jul;
11(27):12965-12972.
PMID: 31259344
With the wide application of Stöber silica nanoparticles and their ability to access the brain, it is crucial to evaluate their neurotoxicity. In this study, we used three in vitro...
2.
Hwang R, Mirshafiee V, Zhu Y, Xia T
Ecotoxicol Environ Saf
. 2018 Oct;
166:294-300.
PMID: 30273853
The surge of applications for engineered nanomaterials (ENMs) across multiple industries raises safety concerns regarding human health and environmental impacts. ENMs can be hazardous through various mechanisms, including, particle dissolution...
3.
Wang X, Lee J, Li R, Liao Y, Kang J, Chang C, et al.
Small
. 2018 May;
14(23):e1703915.
PMID: 29733549
Carbon nanotubes (CNTs) exhibit a number of physicochemical properties that contribute to adverse biological outcomes. However, it is difficult to define the independent contribution of individual properties without purified materials....
4.
Mirshafiee V, Harley B, Kraft M
Tissue Eng Part C Methods
. 2018 Apr;
24(6):322-330.
PMID: 29652627
Characterization of the heterogeneity within stem cell populations, which affects their differentiation potential, is necessary for the design of artificial cultures for stem cell expansion. In this study, we assessed...
5.
Mirshafiee V, Sun B, Chang C, Liao Y, Jiang W, Jiang J, et al.
ACS Nano
. 2018 Mar;
12(4):3836-3852.
PMID: 29543433
The liver and the mononuclear phagocyte system are a frequent target for engineered nanomaterials, either as a result of particle uptake and spread from primary exposure sites or systemic administration...
6.
Sun B, Ji Z, Liao Y, Chang C, Wang X, Ku J, et al.
ACS Appl Mater Interfaces
. 2017 Jun;
9(26):21697-21705.
PMID: 28590715
Aluminum-salt-based vaccine adjuvants are prevailingly used in FDA-approved vaccines for the prevention of infectious diseases for over eighty years. Despite their safe applications, the mechanisms regarding how the material characteristics...
7.
Mirshafiee V, Jiang W, Sun B, Wang X, Xia T
Mol Ther
. 2017 Apr;
25(7):1522-1530.
PMID: 28412168
Extensive research on engineered nanomaterials (ENMs) has led to the development of numerous nano-based formulations for theranostic purposes. Although some nano-based drug delivery systems already exist on the market, growing...
8.
Mirshafiee V, Kim R, Mahmoudi M, Kraft M
Int J Biochem Cell Biol
. 2015 Dec;
75:188-95.
PMID: 26643610
Nanoparticle (NP) exposure to biological fluids in the body results in protein binding to the NP surface, which forms a protein coating that is called the "protein corona". To simplify...
9.
Mirshafiee V, Kim R, Park S, Mahmoudi M, Kraft M
Biomaterials
. 2015 Oct;
75:295-304.
PMID: 26513421
Nanoparticles (NPs) are functionalized with targeting ligands to enable selectively delivering drugs to desired locations in the body. When these functionalized NPs enter the blood stream, plasma proteins bind to...
10.
Mirshafiee V, Mahmoudi M, Lou K, Cheng J, Kraft M
Chem Commun (Camb)
. 2013 Feb;
49(25):2557-9.
PMID: 23423192
When nanoparticles (NPs) are exposed to the biological environment, their surfaces become covered with proteins and biomolecules (e.g. lipids). Here, we report that this protein coating, or corona, reduces the...